Literature DB >> 1491400

Clinical manifestations of the antiphospholipid syndrome.

D Alarcón-Segovia1.   

Abstract

We studied a large cohort of patients with systemic lupus erythematosus (SLE) to determine which manifestations associate with the antiphospholipids (aPL) and to ascertain when 2 or more such manifestations coexist, the association with aPL is stronger and the titers tend to be higher. We have confirmed that when aPL occur within SLE, they may account for some disease manifestations. We also described a similar syndrome occurring in the absence of a primary condition which we termed primary antiphospholipid syndrome (APS). Thus, we were able to construct preliminary criteria for the classification of APS as it occurs in SLE. With appropriate additions and exclusions to rule out SLE, these criteria could be applied to the classification of primary APS.

Entities:  

Mesh:

Year:  1992        PMID: 1491400

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

1.  Clinical features associated with a positive anticardiolipin antibody in Irish patients with systemic lupus erythematosus.

Authors:  I S Gourley; S A McMillan; A L Bell
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

2.  Anti-phospholipid antibodies and CD5+ B cells in HIV infection.

Authors:  T Grünewald; G R Burmester; W Schüler-Maué; F Hiepe; F Buttgereit
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

3.  Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome.

Authors:  Ayse Cefle; Murat Inanc; Mehmet Sayarlioglu; Sevil Kamali; Ahmet Gul; Lale Ocal; Orhan Aral; Meral Konice
Journal:  Rheumatol Int       Date:  2009-12-11       Impact factor: 2.631

4.  Acute transverse myelitis and primary urticarial vasculitis.

Authors:  G Bolla; P Disdier; D Verrot; L Swiader; L Andrac; J R Harlé; J Pouget; P J Weiller
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.